Leerink Partnrs Issues Positive Forecast for Natera Earnings

Natera, Inc. (NASDAQ:NTRA) – Stock analysts at Leerink Partnrs increased their FY2024 EPS estimates for Natera in a research note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of ($1.61) per share for the year, up from their prior estimate of ($1.83). The consensus estimate for Natera’s current full-year earnings is ($1.96) per share. Leerink Partnrs also issued estimates for Natera’s Q4 2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.18) EPS and FY2026 earnings at ($0.40) EPS.

Several other analysts have also weighed in on the company. Sanford C. Bernstein lifted their price objective on Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. lifted their price target on shares of Natera from $135.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday. Piper Sandler restated an “overweight” rating and issued a $150.00 price objective on shares of Natera in a research note on Friday, September 13th. Leerink Partners upped their target price on shares of Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Finally, Canaccord Genuity Group raised their price target on shares of Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus price target of $137.65.

Natera Stock Down 3.3 %

NTRA stock opened at $146.06 on Friday. The business’s 50-day simple moving average is $127.38 and its 200 day simple moving average is $115.46. The company has a quick ratio of 4.01, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company has a market cap of $19.28 billion, a PE ratio of -82.99 and a beta of 1.53. Natera has a twelve month low of $52.01 and a twelve month high of $167.79.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business’s revenue was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.95) EPS.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 5,024 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the transaction, the chief executive officer now owns 195,686 shares of the company’s stock, valued at approximately $25,141,737.28. This represents a 2.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rowan E. Chapman sold 2,614 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $127.68, for a total value of $333,755.52. Following the completion of the transaction, the director now owns 7,969 shares in the company, valued at $1,017,481.92. The trade was a 24.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 36,821 shares of company stock worth $4,776,878. Insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Natera

Several large investors have recently made changes to their positions in NTRA. Covestor Ltd lifted its position in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares during the period. GAMMA Investing LLC lifted its holdings in Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares during the period. CIBC Asset Management Inc boosted its stake in Natera by 3.3% in the third quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock valued at $441,000 after acquiring an additional 111 shares during the last quarter. RiverPark Advisors LLC grew its holdings in Natera by 3.5% during the 3rd quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company’s stock worth $425,000 after acquiring an additional 112 shares during the period. Finally, Moss Adams Wealth Advisors LLC raised its position in shares of Natera by 5.4% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock valued at $336,000 after acquiring an additional 135 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.